By the time someone notices their sight is failing, significant damage has already occurred.
In the world's diabetes capital, a silent epidemic is unfolding behind the eyes of millions. Diabetic retinopathy — damage wrought by years of elevated blood sugar on the retina's delicate vessels — has become India's leading cause of vision loss, advancing without warning until sight is already slipping away. With only one in ten diabetics ever having their eyes examined, the distance between a treatable condition and irreversible blindness is measured not in medicine, but in awareness and access. What is preventable is becoming permanent, and the human cost of that gap is only beginning to be counted.
- A detection crisis is unfolding quietly: 17% of Indian diabetics have retinopathy, yet only 10% have ever had a retinal screening — meaning millions are going blind without knowing they are at risk.
- The disease's silence is its cruelty — no pain, no early warning, just slow vascular damage accumulating until the moment vision fails and the window for full recovery has already closed.
- Blindness here is not only a medical outcome but a social one — it dismantles livelihoods, strips independence, and sends economic shockwaves through families already navigating the burden of chronic illness.
- New bispecific antibody therapies are offering a more powerful and efficient treatment path, targeting multiple disease mechanisms at once and reducing the number of interventions patients require.
- Experts are pressing for 80% screening coverage among diabetics by 2030, calling for retinal exams to become a standard feature of diabetes care and for public campaigns to close the awareness gap before it widens further.
India's diabetes epidemic is quietly producing a second crisis — one measured in lost sight. Diabetic retinopathy, caused by chronic high blood sugar damaging the retina's blood vessels, has become the country's leading driver of vision loss. The condition progresses in stages: vessels weaken, leak, and bleed; the retina swells; scar tissue forms; abnormal vessels grow. By the time a person notices something is wrong, irreversible damage is often already done.
The scale of the detection gap is alarming. A 2019 national survey found that roughly 17% of Indians over 50 with diabetes have developed retinopathy — yet only about 10% of diabetics have ever had their retinas examined. Specialists at AIIMS and the Vitreo-Retinal Society of India have been direct: this is a public health emergency hiding behind a lack of awareness, and the delay between onset and diagnosis is where preventable blindness takes hold.
The consequences reach beyond vision. Blindness disrupts work, erodes autonomy, and diminishes quality of life in ways that ripple through households and communities. In a country where diabetes is still spreading, the compounding burden is significant.
Treatment options are improving — bispecific antibodies now offer a way to target multiple disease pathways simultaneously, requiring fewer interventions than older approaches. But experts are clear that technology alone cannot close the gap. They are calling for systematic screening programs, routine eye exams as part of standard diabetes care, and a national target of reaching 80% of diabetics by 2030. The path to preventing this blindness already exists. The urgency is in choosing to walk it.
India has a diabetes problem that is quietly stealing people's sight. Diabetic retinopathy—damage to the blood vessels in the retina caused by persistently high blood sugar—is now the leading cause of vision loss in the country, and most people don't know they have it until they've already started to go blind.
The numbers tell a stark story. According to the National Blindness and Visual Impairment Survey conducted in 2019 by the RP Centre at AIIMS in New Delhi, nearly 12 percent of Indians aged 50 and older have diabetes. Among that group, roughly 17 percent have developed diabetic retinopathy. But here's the crisis within the crisis: only about 10 percent of people with diabetes have ever had their retinas examined to check for the condition. That gap between who has the disease and who knows they have it is where preventable blindness happens.
What makes diabetic retinopathy particularly dangerous is its silence. In the early stages, it causes no obvious symptoms. A person's blood sugar stays elevated, day after day, and the small blood vessels in the retina—the light-sensitive tissue at the back of the eye—begin to weaken. Over time, these vessels leak fluid or bleed. The retina swells. Scar tissue forms. New, abnormal blood vessels grow. A condition called diabetic macular edema can develop, threatening central vision. By the time someone notices their sight is failing, significant and sometimes irreversible damage has already occurred.
Dr. Praveen Vashist, a professor of community ophthalmology at AIIMS, put it plainly: diabetic retinopathy is rapidly emerging as a major public health problem in India, one of the leading causes of visual impairment in the country. Dr. Vishali Gupta, vice president of the Vitreo-Retinal Society of India and head of retina services at PGIMS, emphasized that the condition remains unrecognized until vision loss has already set in—a delay that can mean the difference between treatable disease and irreversible blindness.
The consequences extend beyond the eye. When diabetic retinopathy progresses to complete blindness, it strips away independence. It diminishes quality of life. It erodes economic productivity. A person who loses their sight cannot work as they did before. They cannot move through the world with the same autonomy. The damage ripples outward.
There is some hope in new treatments. Laser therapy and anti-VEGF injections have long been the standard approach for diabetic macular edema. But bispecific antibodies—a newer class of drug—are changing the picture. These medications target multiple disease pathways at once, reducing inflammation, controlling abnormal vessel growth, and preserving vision with fewer treatments required. In a country where diabetes is spreading rapidly, these innovations matter.
But innovation alone won't solve the problem. Experts are calling for a nationwide screening initiative, with a realistic target of reaching at least 80 percent of people with diabetes by 2030. They're urging regular eye check-ups as a routine part of diabetes care. They're demanding public awareness campaigns and systematic screening programs. The message is clear: early detection changes everything. Caught early, diabetic retinopathy can be managed. Caught late, it takes your sight.
India is the diabetes capital of the world. That status comes with a responsibility to see the crisis unfolding in plain sight—and to act before more people lose theirs.
Citações Notáveis
Diabetic retinopathy is rapidly emerging as a public health problem and one of the leading causes of visual impairment in the country— Dr. Praveen Vashist, Professor of Community Ophthalmology, AIIMS New Delhi
Delayed screening and diagnosis mean patients often present when significant and sometimes irreversible damage has already occurred, potentially leading to complete blindness and loss of independence— Dr. Vishali Gupta, Vice President, Vitreo-Retinal Society of India
A Conversa do Hearth Outra perspectiva sobre a história
Why does diabetic retinopathy progress without symptoms? That seems like a design flaw in how the body warns us of danger.
The retina doesn't have pain receptors. Blood vessel damage happens slowly, at the cellular level, in tissue that can't send distress signals the way other parts of the body can. By the time vision actually blurs, the damage is often months or years old.
So screening is the only real early warning system.
Exactly. A simple retinal examination can catch it when the vessels are just beginning to leak, when treatment can still prevent blindness. But only 10 percent of Indian diabetics are getting screened.
Why such a low number? Is it cost, access, or awareness?
Probably all three. Many people don't know they need the screening. Rural areas lack eye care infrastructure. And if you're already managing diabetes with medications and doctor visits, adding another specialist appointment feels like a burden.
These new bispecific antibody treatments sound promising. Will they solve the problem?
They're a real advance—fewer injections, better outcomes. But they only work if you catch the disease early enough. A drug can't restore vision that's already gone. Prevention through screening is still the foundation.
What does 80 percent screening coverage by 2030 actually require?
A coordinated national effort. Training more eye care workers. Setting up screening camps in rural areas. Public health campaigns that reach people where they are. It's ambitious, but it's the only way to prevent millions of preventable cases of blindness.